Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (763)	12/3/1999 4:56:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 4474

Mike, I agree that the Ariad systems are much less likely to do harm than the systems that are currently being tested. I'm trying to explain why ARIA is trading below a buck and a half when they have such an undisputedly high technology value (to everyone except the street that is <sigh>) and what is about to become a clean balance sheet. I was wondering whether the negative press is weighing on investors and moving them away from gene therapy companies in general and ARIA is simply getting caught in the downdraft. I was also wondering if this might be weighing negatively on partnership negotiations. Pharma might want to have the smoke clear before stepping up to the plate (sorry for the mixed metaphor <g>). This death has put a cloud over the whole area and I'm just trying to ascertain if this is responsible for the miserable recent performance of ARIA. Have a great weekend John de C